NASDAQ · Biotechnology

Corcept Therapeutics Incorporated (CORT) Stock

$110.16 -2.83% NASDAQ: CORT Healthcare

Valuation

MetricValue
Price$110.16
Market Cap$11.91B
P/E Ratio221.60
P/B Ratio17.20
P/S Ratio14.99
EPS (TTM)$0.00
52-Week High$126.38
52-Week Low$28.66
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE8.37%
ROA6.18%
ROCE0.87%
Gross Margin98.25%
Operating Margin-30.08%
Net Margin6.61%
Debt/Equity0.01
Current Ratio2.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$366.0M$402.0M$482.0M$675.0M$761.0M
Operating Profit$124.0M$113.0M$107.0M$137.0M$45.0M
Net Profit$113.0M$101.0M$106.0M$140.0M$100.0M
EPS$0.89$0.87$0.94$1.23$0.82
Op Margin34.0%28.0%22.2%20.3%5.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$424.0M$583.0M$622.0M$841.0M$837.0M
Total Liabilities$48.0M$82.0M$115.0M$161.0M$189.0M
Cash$78.0M$66.0M$136.0M$128.0M$120.0M
Borrowings$1.0M$1.0M$0$7.0M$6.0M

Latest News

CORT: Lowering target price to $95.00 Argus Research · Jul 15, 2026 Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook Motley Fool · Jul 12, 2026 Why Crinetics Stock Soared 99% This Week 24/7 Wall St. · Jul 9, 2026 3 Cash-Heavy Stocks with Questionable Fundamentals StockStory · Jul 7, 2026 3 High-Flying Stocks We Steer Clear Of StockStory · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$168.0M$120.0M$127.0M$198.0M$142.0M
Investing Cash Flow$136.0M$-115.0M$91.0M$-180.0M$70.0M
Financing Cash Flow$-303.0M$-17.0M$-149.0M$-38.0M$-220.0M
Net Cash Flow$1.0M$-11.0M$69.0M$-8.0M$-7.0M
Free Cash Flow$167.0M$120.0M$127.0M$196.0M$142.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-3.77
EV / EBITDA429.14
FCF Yield0.86%
Quick Ratio2.77
Interest Coverage—
Return 1Y63.86%
Return 3Y339.73%
Return 5Y474.91%

Ownership

Insiders Held11.54%
Institutions Held75.57%
Institutions Float Held85.43%
Institutional HolderSharesReport Date
Blackrock Inc.12,151,2762026-03-31
Ingalls & Snyder LLC7,608,7162026-03-31
Renaissance Technologies, LLC5,682,7832026-03-31
Vanguard Portfolio Management LLC4,820,5682026-03-31
Vanguard Capital Management LLC4,077,1962026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
MBXMBX Biosciences, Inc. $49.61 -2.17% -24.38 $2.39B 0.00%
SPRBSpruce Biosciences, Inc. $39.65 -4.39% -1.12 $113.95M 0.00%

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is led by CEO Joseph K. Belanoff, employs 730 people, headquartered in Redwood City, US, publicly traded since 2004.

Corcept Therapeutics Incorporated (CORT) stock trades at $110.16 with a market capitalization of $11.91B. The stock is valued at a price-to-earnings (P/E) ratio of 221.60, price-to-book of 17.20, price-to-sales of 14.99. Over the past 52 weeks the stock has ranged between $28.66 and $126.38, and currently trades 12.8% below its 52-week high.

On profitability, Corcept Therapeutics Incorporated generates a return on equity (ROE) of 8.37%, return on capital employed of 0.87%, an operating margin of -30.08%, a net profit margin of 6.61%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.